This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción ESAL.Y
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Competidores de Eisai Co., Ltd.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥61.51 |
| 52 Week High | JP¥73.90 |
| 52 Week Low | JP¥36.88 |
| Beta | 0.21 |
| 1 Month Change | -7.24% |
| 3 Month Change | 2.28% |
| 1 Year Change | 19.69% |
| 3 Year Change | -28.69% |
| 5 Year Change | 9.25% |
| Change since IPO | 208.81% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| ESAL.Y | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | -4.4% | -1.4% | -3.2% |
| 1Y | 19.7% | 9.7% | 19.3% |
Rentabilidad vs. Industria: ESAL.Y exceeded the US Pharmaceuticals industry which returned 3.2% over the past year.
Rentabilidad vs. Mercado: ESAL.Y exceeded the US Market which returned -12.5% over the past year.
Volatilidad de los precios
| ESAL.Y volatility | |
|---|---|
| ESAL.Y Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: ESAL.Y has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: ESAL.Y's weekly volatility (6%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1941 | 11,322 | Haruo Naito | www.eisai.co.jp |
Resumen de fundamentos de Eisai Co., Ltd.
| Estadísticas fundamentales de ESAL.Y | |
|---|---|
| Capitalización bursátil | US$17.66b |
| Beneficios(TTM) | US$247.68m |
| Ingresos (TTM) | US$5.78b |
71.3x
Ratio precio-beneficio (PE)3.1x
Ratio precio-ventas (PS)¿Está ESAL.Y sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ESAL.Y | |
|---|---|
| Ingresos | JP¥752.50b |
| Coste de los ingresos | JP¥187.50b |
| Beneficio bruto | JP¥565.00b |
| Otros gastos | JP¥532.77b |
| Beneficios | JP¥32.23b |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
Feb 06, 2023
| Beneficios por acción (BPA) | 112.35 |
| Margen bruto | 75.08% |
| Margen de beneficio neto | 4.28% |
| Ratio deuda/patrimonio | 11.2% |
¿Cómo se ha desempeñado ESAL.Y a largo plazo?
Ver rendimiento histórico y comparativa